Baron Health Care Fund Q3 2024 Shareholder Letter [Seeking Alpha]
Arcellx, Inc. (ACLX)
Company Research
Source: Seeking Alpha
ICLR JNJ BMY ACLX ARGX UNH COO HCA DXCM MRK LLY ISRG BSX TMO VRTX DHR SYK REGN PCVX INSM RARE TEM THC RDNT ARGNF UNH:CA TMO:CA BMYMP CELG.RT LLY:CA JNJ:CA ISRG:CA BPTRX BGAFX BREFX BIOPX BGRFX BARAX BPTIX BFGFX BEXIX BDFFX BGRIX BEXFX BARIX BSCFX BCAP BFTHX BGAIX BWBFX BDFIX BREIX BSFIX BROE BFGIX BIGFX BIOIX BRIFX BWBIX BFINX BINIX BRIIX BDAIX BARUX BFIIX BFTIX BEXUX BGLUX BPTUX BRIUX BWBTX IBCGX IBSAX BFTUX BREUX BDFUX BFGUX BIGUX BDAFX BTEEX Baron Capital Follower s Follow Summary Baron Health Care Fund advanced in the third quarter of 2024, although it trailed its benchmark, the Russell 3000 Health Care Index. Top contributors included Arcellx, Inc., argenx SE, and UnitedHealth Group Incorporated. Top detractors were Edwards Lifesciences Corporation, iRhythm Technologies, Inc., and DexCom, Inc. We initiated positions in four biotechnology companies during the quarter: industry pioneer Regeneron Pharmaceuticals, Inc., Vaxcyte, Inc. (vaccines), Insmed Incorporated (
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]Yahoo! Finance
- Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.MarketBeat
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 11/7/24 - Beat
ACLX
Sec Filings
- 12/12/24 - Form 8-K
- 12/9/24 - Form 8-K
- 12/5/24 - Form 4
- ACLX's page on the SEC website